Novel 1,2,4‐Triazole–Thiopyrimidine Hybrids as COX‐2 Inhibitors: Synthesis, ADME Profiling, Antioxidant Activity, and Molecular Docking
BioMed Research International · 2026-01 · 2026 (1)
DOI: 10.1155/bmri/4477854 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, online erschienen am 31.03.2026. Verfasst von Yuriy Karpenko und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicological and Inorganic Chemistry, Faculty of Pharmacy, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukr…. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Triazoles, Antioxidants, Cyclooxygenase 2 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: President of Ukraine.
Abstract (Originalsprache)
This work reports the design, synthesis, and multilevel evaluation of 20 new S‐alkyl derivatives of 6‐(5‐mercapto‐4‐ethyl‐4H‐1,2,4‐triazol‐3‐yl)pyrimidine‐2,4(1H,3H)‐dione as potential selective cyclooxygenase‐2 (COX‐2) inhibitors with antioxidant properties. The aim was to establish structure–property relationships between the S‐alkyl fragment, antioxidant mechanisms, and COX‐2 inhibition and to identify lead structures for further optimization. Compounds were obtained by stepwise construction of the 1,2,4‐triazole fragment from orotic acid, followed by selective S‐alkylation of the mercaptotriazole, and their structures were confirmed by 1 H/ 13 C NMR, LC‐MS, and elemental analysis. Antiradical activity in vitro was assessed by the DPPH assay with determination of percent inhibition and IC 50 , whereas COX‐1/COX‐2 inhibition was evaluated using a fluorescent enzyme assay to obtain IC 50 and selectivity index (SI). Density functional theory (DFT) calculations were employed to compare the thermodynamic feasibility of HAT, SET–PT, and SPLET pathways, while molecular docking and molecular dynamics were used to study the affinity and stability of binding to COX‐1 and COX‐2. A clear increase in antiradical activity was observed in the series 17 < ascorbic acid < 14 < 20 < 13 < 19 , reaching 72.34% DPPH inhibition for Compound 19 with IC 50 (DPPH) = 12.15 ± 3.98 μ M, considerably surpassing ascorbic acid. Compound 19 also exhibited the lowest IC 50 (COX − 2) = 24.5 ± 0.9 μ M with SI ≈ 8.2; Compounds 13 and 20 showed moderate COX‐2 selectivity (SI ≈ 1.2–1.3), whereas 14 and 17 had a COX‐1‐shifted profile reminiscent of classical NSAIDs. DFT analysis indicated predominance of the SPLET mechanism for most systems, with the lowest Δ G values for 19 and 20 , consistent with their high antioxidant activity. The combined experimental and in silico data identify Compound 19 as a primary lead candidate that combines potent antioxidant effects with pronounced, selective COX‐2 inhibition and highlight 13 and 20 as promising backup structures for further preclinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Toxicological and Inorganic Chemistry, Faculty of Pharmacy, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
- Department of Clinical Pharmacy, Pharmacotherapy, Pharmacognosy and Pharmaceutical Chemistry, Faculty of Pharmacy, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
- Department of Drug Technology, Faculty of Pharmacy, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
- Department of Obstetrics, Gynecology and Reproductive Medicine, Faculty of Medicine, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
- Department of Physicocolloid and Analytical Chemistry, Faculty of Pharmacy, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
- Department of Industrial Pharmacy, Kyiv National University of Technology and Design, Kyiv, Ukraine.
ORCID-Profile: Yuriy Karpenko
Förderung
- President of Ukraine
Zitieren
APA
Karpenko, Y., Parchenko, V., Panasenko, O., Bihdan, O., Pukhalska, I., Nikiforov, O., Nahorna, N., Nahornyi, V., & Roik, O. (2026). Novel 1,2,4‐Triazole–Thiopyrimidine Hybrids as COX‐2 Inhibitors: Synthesis, ADME Profiling, Antioxidant Activity, and Molecular Docking. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/4477854
Vancouver
Karpenko Y, Parchenko V, Panasenko O, Bihdan O, Pukhalska I, Nikiforov O, et al. Novel 1,2,4‐Triazole–Thiopyrimidine Hybrids as COX‐2 Inhibitors: Synthesis, ADME Profiling, Antioxidant Activity, and Molecular Docking. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/4477854
BibTeX
@article{Karpenko2026,
author = {Karpenko, Yuriy and Parchenko, Volodymyr and Panasenko, Olexandr and Bihdan, Oleksii and Pukhalska, Iryna and Nikiforov, Oleg and Nahorna, Nataliia and Nahornyi, Volodymyr and Roik, Olena},
title = {Novel 1,2,4‐Triazole–Thiopyrimidine Hybrids as COX‐2 Inhibitors: Synthesis, ADME Profiling, Antioxidant Activity, and Molecular Docking},
journal = {BioMed Research International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/bmri/4477854}
}
EUVIMED